Clinical Trial Update: Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of rituximab and LMP-specific T cells for EBV-positive, CD20-positive post-transplant lymphoproliferative disorder in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disorder

Drugs mentioned

• LMP-specific T cells (LMP-specific T cells)
• Rituxan (rituximab)

Snippet

Sponsor: Children's Oncology Group | Conditions: EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder | Phase 2 | Status: COMPLETED | Results posted: 2022-06-03